Local News

• Ondine announces FDA confirmation of regulatory pathway for Periowave(TM)  Ondine Biopharma announced it has received confirmation from the U.S. Food & Drug Administration (FDA) that the Company's Periowave(TM) Photodisinfection System will be evaluated as a Class III medical device under premarket approval (PMA) regulations.
  Ondine Biopharma Corporation August 27, 2008  
• Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer  Cell Genesys announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer.
  Cell Genesys, Inc. August 27, 2008  
• Amylin Pharmaceuticals and Eli Lilly provide context for FDA alert for BYETTA  Amylin Pharmaceuticals and Eli Lilly and Company in a conference call provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis.
  Amylin Pharmaceuticals, Inc. August 26, 2008  
• Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program  Bristol-Myers Squibb Company and Pfizer provided an update on the apixaban clinical development program. The companies announced that new Phase II data in acute coronary syndrome patients (ACS) will be presented at the upcoming meeting of the European Society of Cardiology (ESC).
  Pfizer Inc. August 26, 2008  
• Gen-Probe announces $250 million stock repurchase plan  Gen-Probe announced that its board of directors has authorized the repurchase of up to $250 million of the Company's common stock over the next two years.
  Gen-Probe Incorporated August 26, 2008  
• VYVANSE(R) now available in U.S. pharmacies nationwide in six dosage strengths  Shire Limited has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.
  Shire August 26, 2008  
• Physio-Control endows the James O. Page Collection as sole Founding Benefactor  Physio-Control, a wholly owned subsidiary of Medtronic, announced it has endowed the newly-established James O. Page Collection, the beginnings of a national Emergency Medical Services (EMS) library at UCLA as the sole Founding Benefactor.
  Medtronic, Inc. August 26, 2008  
• Applied Biosystems expands sequencing-based RNA analysis solutions portfolio  Applied Biosystems announced the development of a sequencing-based molecular tool for the genomic analysis of whole transcriptomes, the vast collection of RNAs transcribed from a genome.
  Applied Biosystems Inc. August 26, 2008  
• QLT announces agreement to exclusively license the Atrigel(R) technology  QLT Inc. announced that QLT USA, its wholly-owned subsidiary, has entered into an exclusive license agreement with Reckitt Benckiser Pharmaceuticals for its Atrigel(R) sustained-release drug delivery technology, except for certain rights being retained by QLT USA and its prior licensees.
  QLT Inc. August 26, 2008  
• Stanford to limit drug maker financing  Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce that it will severely restrict industry financing of doctors' continuing education at its medical school.
  The New York Times August 25, 2008  Gardiner Harris

   (next 10 articles)